文献速递关节外科

口服可溶膜剂昂丹司琼在全关节置换术后恶心呕吐预防中优于静脉昂丹司琼:一项前瞻性随机对照研究

Orally Soluble Pellicles (OSPs) Are More Effective than Intravenous (IV) Ondansetron in Prophylaxis of Postoperative Nausea and Vomiting (PONV) After Primary Total Joint Arthroplasty (TJA): A Prospective Randomized Controlled Study.
PubMed 文献 · J Arthroplasty · 2025-08-06

前瞻性随机对照研究纳入150例全麻下初次全关节置换术患者,分为对照组、口服可溶膜剂昂丹司琼组和静脉昂丹司琼组,比较术后48小时内恶心呕吐的发生率和严重程度。口服膜剂组在术后12至18小时恶心频率显著低于对照组,患者满意度评分显著高于静脉组,预防呕吐疗效与静脉制剂相当。

要点

  • 口服可溶膜剂昂丹司琼预防全关节置换术后呕吐的疗效与静脉制剂相当
  • 口服膜剂组术后12至18小时恶心频率显著低于对照组
  • 口服膜剂组患者满意度评分显著高于静脉组

核心结论

  • 口服可溶膜剂昂丹司琼预防全麻下全关节置换术后呕吐的疗效与静脉制剂相当,且抗恶心效果优于静脉制剂,患者满意度评分更高。

研究设计与样本

  • 前瞻性随机对照研究,共纳入150例接受全关节置换术的患者,随机分为三组:对照组、口服可溶膜剂昂丹司琼组和静脉昂丹司琼组。

主要发现

  • 与对照组相比,口服膜剂组和静脉组在术后6小时内恶心呕吐的频率和严重程度均显著降低,经口进食恢复更早,止吐药补救需求更少,患者满意度评分更高。
  • 口服膜剂组术后12至18小时恶心频率显著低于对照组。
  • 口服膜剂组患者满意度评分显著高于静脉组。

关键数值与推荐

  • 口服可溶膜剂昂丹司琼组:麻醉诱导前1小时给予16 mg,术后两天每日两次每次8 mg。
  • 静脉昂丹司琼组:麻醉诱导时给予8 mg,术后两天每日一次每次8 mg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the orally soluble pellicle (OSP) of ondansetron emerging as a novel and increasingly prescribed alternative for controlling postoperative nausea and vomiting (PONV), its superiority over its intravenous (IV) counterpart in preventing PONV remains to be definitively established. Herein, we conducted a study to compare the efficacy of OSP versus IV ondansetron in the prophylaxis of PONV following primary total joint arthroplasty (TJA) under general anesthesia. METHODS: A total of 150 patients undergoing TJA were randomly assigned to one of three groups: a control group, an OSP ondansetron group (16 mg administered one hour before anesthesia induction, followed by eight mg twice daily for two postoperative days), and an IV ondansetron group (eight mg administered at anesthesia induction, followed by eight mg once daily for two postoperative days). The primary outcome was the incidence and severity of PONV within the first 48 hours postoperatively. Secondary outcomes included the time to resumption of oral intake, the dosage of rescue medications (tramadol and metoclopramide), patient satisfaction scores at discharge, serum levels of inflammatory biomarkers, and the incidence of complications. RESULTS: Compared with the control group, both the OSP and IV groups demonstrated significantly lower frequency and severity of PONV within the first six hours postoperatively, as well as earlier resumption of oral intake, lower requirements for rescue antiemetics, and higher patient satisfaction scores. In addition, the OSP group showed a significantly lower frequency of nausea during the 12 to 18 hours postoperatively compared with the control group. Furthermore, the OSP group had significantly higher patient satisfaction scores than those in the IV group. CONCLUSIONS: The OSP ondansetron demonstrated comparable efficacy to IV formulations in preventing vomiting following TJA under general anesthesia. Notably, OSP ondansetron not only exhibited superior antinausea effects compared to its IV counterpart but also achieved higher patient satisfaction scores.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Zhao L, Xie J, Zhang J, et al. Orally Soluble Pellicles (OSPs) Are More Effective than Intravenous (IV) Ondansetron in Prophylaxis of Postoperative Nausea and Vomiting (PONV) After Primary Total Joint Arthroplasty (TJA): A Prospective Randomized Controlled Study. J Arthroplasty. 2025. PMID: 40780485. doi:10.1016/j.arth.2025.07.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。